Jeremy Skillington of Poolbeg Pharma: POLB 001 LPS human challenge clinical trial successfully completed
Episode 1073, Dec 12, 2022, 07:21 AM
Jeremy Skillington, CEO of Poolbeg Pharma #POLB says they have now received the initial results, having completed the LPS human challenge clinical trial for POLB 001, and it was found to be safe and well tolerated.
Highlights
· No further clinical activity is required to complete the objectives of the trial, bringing the recruitment and clinical phase to a close on schedule
· No serious adverse events reported. POLB 001 was found to be safe and well tolerated
· Data analysis has commenced and full data read-out is expected in Q2 2023
· The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners
To read the entire RNS click here
Highlights
· No further clinical activity is required to complete the objectives of the trial, bringing the recruitment and clinical phase to a close on schedule
· No serious adverse events reported. POLB 001 was found to be safe and well tolerated
· Data analysis has commenced and full data read-out is expected in Q2 2023
· The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners
To read the entire RNS click here